We are live on ! Find out more
AIM icon

AIM ImmunoTech
AIM

16 hedge funds and large institutions have $434K invested in AIM ImmunoTech in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more funds holding

Funds holding: 13 → 16 (+3)

0.52% less ownership

Funds ownership: 4.47% → 3.95% (-0.52%)

20% less capital inflows, than outflows

Capital inflows: $57.5K | Capital outflows: $71.9K

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
16
Holders Change
+3
Holders Change %
+23.08%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Securities
Two Sigma Securities
New York
+$25.9K
2
Citadel Advisors
Citadel Advisors
Florida
+$15.8K
3
Virtu Financial
Virtu Financial
New York
+$12.9K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.44K
5
UBS Group
UBS Group
Switzerland
+$1.44K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$61.8K
2
Renaissance Technologies
Renaissance Technologies
New York
-$8.63K
3
Guggenheim Capital
Guggenheim Capital
Illinois
-$1.44K

AIM Hedge Fund Activity: Q4 2017 in Review

16 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q4 2017, worth a combined $434K — up 3.3% from $420K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new AIM positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $25.9K. The largest seller was Vanguard Group, cutting an estimated $61.8K.

  • 16 institutional investors held AIM ImmunoTech (AIM) as of Q4 2017, up from 13 in Q3 2017.
  • Funds reported $434K of AIM ImmunoTech stock for Q4 2017, up 3.3% quarter-over-quarter.
  • 3 funds opened new AIM ImmunoTech positions in Q4 2017 and 0 closed out, a net change of +3 holders.
  • The largest AIM ImmunoTech buyer in Q4 2017 was Two Sigma Securities, an estimated $25.9K added.
  • The largest AIM ImmunoTech seller in Q4 2017 was Vanguard Group, an estimated $61.8K sold.

Based on aggregated 13F filings for Q4 2017.